Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02713529 | Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer | completed | Phase 1 / Phase 2 | 117 | AmMax Bio, Inc.INDUSTRY | 6 | Jan 20, 2023 | clinicaltrials |
| NCT01859026 | A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation | completed | Phase 1 | 43 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT04444427 | Evaluation of GLR2007 for Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 19 | Gan and Lee Pharmaceuticals, USAINDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT01177397 | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | completed | Phase 1 / Phase 2 | 226 | CelgeneINDUSTRY | 4 | Dec 13, 2022 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT05631678 | Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole | completed | Phase 1 | 48 | Jiangsu Aosaikang Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 30, 2022 | clinicaltrials |
| NCT03360929 | Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759 | completed | Phase 1 / Phase 2 | 15 | LYZZ Alpha Holding LtdINDUSTRY | 1 | Nov 25, 2022 | clinicaltrials |
| NCT02857270 | A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | completed | Phase 1 | 210 | Eli Lilly and CompanyINDUSTRY | 4 | Nov 22, 2022 | clinicaltrials |
| NCT02555007 | Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC or MPM(NVB Metro) | completed | Phase 1 | 30 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT02908750 | Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC | completed | Phase 1 | 24 | AstraZenecaINDUSTRY | 3 | Nov 14, 2022 | clinicaltrials |
| NCT01982955 | Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT) | completed | Phase 1 / Phase 2 | 88 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 7 | Nov 8, 2022 | clinicaltrials |
| NCT02039674 | A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) | completed | Phase 1 / Phase 2 | 267 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 8, 2022 | clinicaltrials |
| NCT02835690 | Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032) | completed | Phase 1 | 44 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 26, 2022 | clinicaltrials |
| NCT00199849 | NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine | completed | Phase 1 | 18 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT02898116 | Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 2 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT03164772 | Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC | completed | Phase 1 / Phase 2 | 61 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT03965845 | A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 53 | Calithera Biosciences, IncINDUSTRY | 1 | Sep 19, 2022 | clinicaltrials |
| NCT00602030 | Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC | completed | Phase 1 / Phase 2 | 141 | Syndax PharmaceuticalsINDUSTRY | 1 | Aug 22, 2022 | clinicaltrials |
| NCT02862457 | Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434) | completed | Phase 1 | 34 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 19, 2022 | clinicaltrials |
| NCT02404441 | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 319 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 3, 2022 | clinicaltrials |
| NCT03438318 | Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer | completed | Phase 1 | 29 | Regeneron PharmaceuticalsINDUSTRY | 1 | Aug 3, 2022 | clinicaltrials |
| NCT02926768 | Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors | completed | Phase 1 | 136 | Checkpoint Therapeutics, Inc.INDUSTRY | 5 | Jul 26, 2022 | clinicaltrials |
| NCT01014598 | Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung Metastasis | completed | Phase 1 | 11 | Roswell Park Cancer InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT01854684 | Photodynamic Therapy During Surgery in Treating Patients With Non-small Cell Lung Cancer That Can Be Removed by Surgery | completed | Phase 1 | 8 | Roswell Park Cancer InstituteOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT02071862 | Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | completed | Phase 1 | 210 | Calithera Biosciences, IncINDUSTRY | 1 | Jul 20, 2022 | clinicaltrials |
| NCT02535325 | Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2022 | clinicaltrials |
| NCT03623750 | E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C(EPICAL) | completed | Phase 1 / Phase 2 | 23 | Instituto Oncológico Dr RosellOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT04507906 | Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC | completed | Phase 1 / Phase 2 | 21 | Shanghai Chest HospitalOTHER | 1 | Jun 28, 2022 | clinicaltrials |
| NCT02648724 | Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies | completed | Phase 1 / Phase 2 | 57 | Symphogen A/SINDUSTRY | 6 | Jun 22, 2022 | clinicaltrials |
| NCT04315467 | Intraoperative Imaging of Pulmonary Nodules by SGM-101 | completed | Phase 1 | 10 | Sunil SinghalOTHER | 1 | Jun 16, 2022 | clinicaltrials |
| NCT03023319 | Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | completed | Phase 1 | 6 | Nagla Abdel KarimOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT03386955 | BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 215 | Beta Pharma ShanghaiINDUSTRY | 1 | May 16, 2022 | clinicaltrials |
| NCT02470468 | Evaluation of Safety and Efficacy of DCVAC/LuCa (Immunotherapy of Lung Cancer) in Patients With Metastatic Lung Cancer | completed | Phase 1 / Phase 2 | 105 | SOTIO a.s.INDUSTRY | 2 | May 4, 2022 | clinicaltrials |
| NCT03268057 | VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer(CLASSICAL-Lung) | completed | Phase 1 / Phase 2 | 62 | Vaccinex Inc.INDUSTRY | 1 | May 2, 2022 | clinicaltrials |
| NCT02897778 | Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors | completed | Phase 1 | 30 | Syndax PharmaceuticalsINDUSTRY | 1 | Apr 28, 2022 | clinicaltrials |
| NCT03562871 | IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC | completed | Phase 1 / Phase 2 | 109 | IO BiotechINDUSTRY | 4 | Apr 21, 2022 | clinicaltrials |
| NCT03633110 | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | completed | Phase 1 / Phase 2 | 24 | Genocea Biosciences, Inc.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT01134250 | Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients | completed | Phase 1 / Phase 2 | 48 | Philogen S.p.A.INDUSTRY | 1 | Apr 15, 2022 | clinicaltrials |
| NCT02347917 | A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 28 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT01655225 | A Study of LY3023414 in Participants With Advanced Cancer | completed | Phase 1 | 156 | Eli Lilly and CompanyINDUSTRY | 3 | Apr 8, 2022 | clinicaltrials |
| NCT02088112 | MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC). | completed | Phase 1 | 56 | MedImmune LLCINDUSTRY | 3 | Apr 4, 2022 | clinicaltrials |
| NCT02166242 | Ethaselen for the Treatment of Thioredoxin Reductase High Expression Advanced Non-small Cell Lung Cancers | completed | Phase 1 | 40 | Hunan Province Tumor HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT01061840 | Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer | completed | Phase 1 | 100 | Gradalis, Inc.INDUSTRY | 1 | Mar 15, 2022 | clinicaltrials |
| NCT02526017 | Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers(FPA008-003) | completed | Phase 1 | 313 | Five Prime Therapeutics, Inc.INDUSTRY | 1 | Mar 9, 2022 | clinicaltrials |
| NCT02299505 | Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 306 | Novartis PharmaceuticalsINDUSTRY | 24 | Feb 9, 2022 | clinicaltrials |
| NCT01391143 | Safety Study of MGA271 in Refractory Cancer | completed | Phase 1 | 179 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT02381314 | Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer | completed | Phase 1 | 24 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT05226728 | Pharmacokinetically-guided on the Individualization of Pembrolizumab Administration in the Treatment of Lung Cancer | completed | Phase 1 | 33 | Sun Yat-sen UniversityOTHER | 1 | Feb 7, 2022 | clinicaltrials |
| NCT00967577 | 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors | completed | Phase 1 | 20 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 2, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Jan 20, 2023source: clinicaltrials